Kymab instates first Chief Medical Officer

pharmafile | May 9, 2017 | Appointment | Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Novartis, kymab 

Kymab, a therapeutic antibody company based in Cambridge, UK, has announced that it has appointed Dr Sonia Quaratino as its first Chief Medical Officer. Dr Quaratino will be charged with developing Kymab’s therapeutic antibody portfolio.

Dr Quaratino joins Kymab from Novartis, where she previously worked as Global Clinical Program Leader in Transitional Clinical Oncology. In this role, she was responsible for the clinical development of proprietary therapeutics antibody programmes in immuno-oncology – a role with obvious overlap with her appointment to Kymab.

Beyond working with Novartis in Switzerland, she worked with Merck KGaA in Germany as Senior Medical Director and Immunology Advisor for close to six years.  Prior to this, Dr Quaratino worked within academic institutions with the University of Southampton and Imperial College London.

Dr Sonia Quaratino, newly appointed Chief Medical Officer of Kymab, commented on her appointment: “Kymab’s emerging human antibody pipeline provides great potential to improve patient treatment options in our four main therapeutic areas of focus: immuno-oncology; auto-immunity; haematology and infectious disease. The Kymouse technology that underpins the company contains a full set of human immunoglobulin light and heavy chain genes that can produce 10 trillion different antibodies, thus significantly increasing the chances of finding new best-in-class antibodies. I am pleased and proud to be joining the Kymab team.”

“I am delighted to welcome Sonia to Kymab,” said Dr David Chiswell, CEO of Kymab. “With her demonstrated track record in clinical development and medical affairs, Sonia is a superb addition to Kymab‘s management team as we prepare for our first clinical trials. Sonia’s deep understanding of the global environment in clinical research complement those of Dr Arndt Schottelius, our new Executive VP of R&D who recently joined us from Morphosys.”

Related Content

Ionis and Novartis partner for CVD treatment programme

Ionis Pharmaceuticals has announced that it has entered into a new collaboration and license agreement …


Novartis acquires Chinook Therapeutics for $3.5bn

Swiss pharmaceutical company Novartis has entered into an agreement and plan of merger with US-based …

Novartis Cosentyx® gains positive CHMP opinion for hidradenitis suppurativa

Basel, April 26, 2023 — Novartis announced today that the Committee for Medicinal Products for Human …

Latest content